JP2022527405A5 - - Google Patents
Info
- Publication number
- JP2022527405A5 JP2022527405A5 JP2021560206A JP2021560206A JP2022527405A5 JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5 JP 2021560206 A JP2021560206 A JP 2021560206A JP 2021560206 A JP2021560206 A JP 2021560206A JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832622P | 2019-04-11 | 2019-04-11 | |
| US62/832,622 | 2019-04-11 | ||
| PCT/US2020/027327 WO2020210398A1 (en) | 2019-04-11 | 2020-04-08 | CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527405A JP2022527405A (ja) | 2022-06-01 |
| JPWO2020210398A5 JPWO2020210398A5 (https=) | 2023-04-18 |
| JP2022527405A5 true JP2022527405A5 (https=) | 2023-04-18 |
| JP7783746B2 JP7783746B2 (ja) | 2025-12-10 |
Family
ID=72750569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560206A Active JP7783746B2 (ja) | 2019-04-11 | 2020-04-08 | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184142A1 (https=) |
| EP (1) | EP3953453A4 (https=) |
| JP (1) | JP7783746B2 (https=) |
| KR (1) | KR20210139472A (https=) |
| CN (1) | CN113906133A (https=) |
| AU (1) | AU2020271523A1 (https=) |
| BR (1) | BR112021019772A2 (https=) |
| CA (1) | CA3135224A1 (https=) |
| IL (1) | IL286858A (https=) |
| MX (1) | MX2021012054A (https=) |
| SG (1) | SG11202110601UA (https=) |
| WO (1) | WO2020210398A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| AU2021292695A1 (en) | 2020-06-19 | 2023-02-02 | Fate Therapeutics, Inc. | Combining iPSC-derived effector cell types for immunotherapy use |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| JP2023548467A (ja) * | 2020-11-04 | 2023-11-17 | フェイト セラピューティクス，インコーポレイティド | 操作されたｉＰＳＣ及び持続性免疫エフェクター細胞 |
| JP2023549098A (ja) * | 2020-11-04 | 2023-11-22 | フェイト セラピューティクス，インコーポレイティド | 固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CA3204417A1 (en) * | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| CN117377756A (zh) * | 2021-03-05 | 2024-01-09 | 菲克特生物科学股份有限公司 | 工程化免疫细胞疗法 |
| CN113528453B (zh) * | 2021-07-07 | 2023-05-12 | 金宇保灵生物药品有限公司 | 一种永生化猪巨噬细胞株及其构建方法和应用 |
| GB202110363D0 (en) * | 2021-07-19 | 2021-09-01 | Celyad S A | NKG2D CAR cells expressing IL-18 for adoptive cell therapy |
| EP4504221A4 (en) * | 2022-03-22 | 2026-02-25 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| WO2023233342A2 (en) * | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US20260071238A1 (en) * | 2022-09-02 | 2026-03-12 | Janssen Biotech, Inc. | Materials and processes for engineering hypoimmunogenicity |
| WO2025076485A1 (en) * | 2023-10-05 | 2025-04-10 | Mink Therapeutics, Inc. | Novel invariant natural killer t cells and t cell engager compositions and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248119B2 (en) * | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| EP3134515B1 (en) | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| WO2016007570A2 (en) * | 2014-07-09 | 2016-01-14 | The Regents Of The University Of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
| GB201506642D0 (en) * | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN117070468A (zh) * | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| US11377637B2 (en) * | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| US20200087681A1 (en) * | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| US20210015859A1 (en) * | 2017-12-08 | 2021-01-21 | Fate Therapeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CA3093449A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
-
2020
- 2020-04-08 AU AU2020271523A patent/AU2020271523A1/en active Pending
- 2020-04-08 EP EP20787029.6A patent/EP3953453A4/en active Pending
- 2020-04-08 BR BR112021019772A patent/BR112021019772A2/pt unknown
- 2020-04-08 US US17/438,317 patent/US20220184142A1/en active Pending
- 2020-04-08 KR KR1020217036036A patent/KR20210139472A/ko active Pending
- 2020-04-08 JP JP2021560206A patent/JP7783746B2/ja active Active
- 2020-04-08 SG SG11202110601UA patent/SG11202110601UA/en unknown
- 2020-04-08 WO PCT/US2020/027327 patent/WO2020210398A1/en not_active Ceased
- 2020-04-08 CN CN202080031737.3A patent/CN113906133A/zh active Pending
- 2020-04-08 MX MX2021012054A patent/MX2021012054A/es unknown
- 2020-04-08 CA CA3135224A patent/CA3135224A1/en active Pending
-
2021
- 2021-09-30 IL IL286858A patent/IL286858A/en unknown